Act on Preventing Environmental Pollution of Mercury” (About Mercury-Added Products for New Use)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Physical-Chemical Studies 53 UDC 669.017.776.791.4 Complex Use Of
Physical-Chemical Studies 9 Fedotov K.V., Nikol’skaya N.I. Proektirovanie obogatitel’nyh fabrik: application of fuzzy logic rules. Abstract of thesis for cand. Tech. Sci: Uchebnik dlya vuzov (Designing concentrating factories: A textbook for 05.13.06) / Orenburg State University. Orenburg, 2011, 20. (in Russ.) high schools), Moscow: Gornaya kniga, 2012, 536. (in Russ.) 11 Malyshev V.P., Zubrina Yu.S., Makasheva A.M. Rol’ ehntropii 10 Pol’ko P.G. Sovershenstvovanie upravleniya protsessom Bol’tsmana-Shennona v ponimanii processov samoorganizatsii izmel’cheniya rudnykh materialov s primeneniem pravil nechetkoj (The role of the Boltzmann-Shannon entropy in understanding the logiki. Avtoref. diss. … kand. tekhn. nauk: 05.13.06 (Improving processes of self-organization). Dokl. NAN RK = .Proceedings of the management of the process of grinding ore materials with the NAS of RK. 2016. 6, 53-61. (in Russ.) ТҮЙІНДЕМЕ Ұсақтау теориясы мен флотациялау теориясы әлі күнге дейін жалпылама түсінікке ие емес. Бұл мақалада авторлармен ықтималдылықтық-детерминатталған жоспарлы эксперимент негізінде шарлы диірмендерде ұсақтаудың ықтималдық теориясын пайдалану арқылы бірдей математикалық үлгі аясында флотациялау және ұсақтау үрдістерін кешенді зерттеу әдісі жасалған. Ұсақтау ұзақтығынан, ксантогенаттың шығымынан және флотация ұзақтығынан негізгі концентрат флотациясынан мысты алу, жеке және жалпылама құрамының тәуелділігі алынған. Фракциялық құрамның есептеулері нәтижесінде нақты фракция шығымының төмендеуіне әкеліп соқтыратын, шламды фракцияның шығымын ұлғайту есебінде ұсақтаудың ұзақтығынан мысты бөліп алу және құрамына қарай экстремальды сипаты ұсақтаудың ықтималдық үлгісі бойынша негізделген. Үрдістің көпфакторлы үлгісі алынған және оның негізінде матрица-номограммасы есептелінген, жәнеде ол ұсақтау және флотациялау үрдістерінің тиімді режимдерінің аймағын анықтау арқылы технологиялық карта ретінде пайдаланылуы мүмкін. Түйінді сөздер: дайындау, ұсақтау, флотация, ықтималдылықтық-детерминатталған үлгі, көп факторлы үлгі. -
Vol. 82 Thursday, No. 206 October 26, 2017 Pages 49485–49736
Vol. 82 Thursday, No. 206 October 26, 2017 Pages 49485–49736 OFFICE OF THE FEDERAL REGISTER VerDate Sep 11 2014 19:08 Oct 25, 2017 Jkt 244001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\26OCWS.LOC 26OCWS ethrower on DSK3G9T082PROD with FRONT MATTER WS II Federal Register / Vol. 82, No. 206 / Thursday, October 26, 2017 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Subscriptions: Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Paper or fiche 202–512–1800 Committee of the Federal Register (1 CFR Ch. I). The Assistance with public subscriptions 202–512–1806 Superintendent of Documents, U.S. Government Publishing Office, Washington, DC 20402 is the exclusive distributor of the official General online information 202–512–1530; 1–888–293–6498 edition. Periodicals postage is paid at Washington, DC. Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making Paper or fiche 202–512–1800 available to the public regulations and legal notices issued by Assistance with public single copies 1–866–512–1800 Federal agencies. These include Presidential proclamations and (Toll-Free) Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Assistance with Federal agency subscriptions: Documents are on file for public inspection in the Office of the Email [email protected] Federal Register the day before they are published, unless the Phone 202–741–6000 issuing agency requests earlier filing. -
Mercury: Selenium Interactions and Health Implications
Reviews of specific issues relevant to child development Mercury: selenium interactions and health implications Laura J Raymond, PhD; Nicholas VC Ralston, PhD. University of North Dakota, Grand Forks, North Dakota, USA. Correspondence to Nicholas Ralston, Energy & Environmental Research Center, University of North Dakota, PO Box 9018, Grand Forks, ND 58202-9018, USA. Email [email protected] Abstract and exhibits long-term retention once it gets across (4). These factors exacerbate mercury’s neurotoxicity and conspire to Measuring the amount of mercury present in the environment or intensify the pathological effects in this most important and food sources may provide an inadequate reflection of the potential most vulnerable of the body’s tissues. Destruction of an early for health risks if the protective effects of selenium are not also generation of brain cells will naturally preclude development considered. Selenium's involvement is apparent throughout the of further generations of cells, constraining development of mercury cycle, influencing its transport, biogeochemical exposure, brain and nerve tissues. While these are the expected bioavailability, toxicological consequences, and remediation. consequences from high doses of mercury exposure, the Likewise, numerous studies indicate that selenium, present in many effects of chronic low exposure are undetermined. foods (including fish), protects against mercury exposure. Studies Several episodes of fetal MeHg poisoning have been have also shown mercury exposure reduces the activity of selenium dependent enzymes. While seemingly distinct, these concepts may reported and confirm that the developing fetal brain is actually be complementary perspectives of the mercury-selenium especially susceptible (5-8). However, only in Minamata (9) binding interaction. Owing to the extremely high affinity between and Niigata (10), Japan was the poisoning because of fish mercury and selenium, selenium sequesters mercury and reduces its consumption. -
Li-Ion Polymer Batteries
CM0256 Pervasive Computing Lecture 8 – Power Sources Tom Goodale [email protected] Lecture Outline In this lecture we: Examine power sources for mobile devices What power sources are there ? What are their characteristics ? What are their limitations ? Power Sources Mechanical e.g. clockwork Electrical mains power solar power batteries fuel cell Radiation ? Batteries A battery is a device to store energy and make it available in electrical form. Electricity is produced by a chemical reaction, producing electricity, and some by-products, such as heat or gases. In rechargable batteries this chemical reaction is reversible. Battery Arrangements Strictly, an electrical “battery” is an interconnected array of one or more similar “cells”. In current English usage, however, it is more common to call a single cell used on its own a battery than a cell. For example, a hand lamp (flashlight) (torch) is said to take one or more "batteries" even though they may be D cells. A car battery is a true "battery" because it uses multiple cells. Multiple batteries or cells may also be refered to as a battery pack, such as a set of multi-cell 12 V batteries in an electric vehicle. Battery Arrangements In almost any device that uses batteries, you do not use just one cell at a time. You normally group them together serially to form higher voltages, or in parallel to form higher currents. In a serial arrangement, the voltages add up. In a parallel arrangement, the currents add up. The upper arrangement is called a parallel arrangement. If you assume that each cell produces 1.5 volts, then four batteries in parallel will also produce 1.5 volts, but the current supplied will be four times that of a single cell. -
Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222. -
A Screening-Based Approach to Circumvent Tumor Microenvironment
JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL. -
United States Patent (19) 11 Patent Number: 6,039,940 Perrault Et Al
US0060399.40A United States Patent (19) 11 Patent Number: 6,039,940 Perrault et al. (45) Date of Patent: Mar. 21, 2000 54) INHERENTLY ANTIMICROBIAL 5,563,056 10/1996 Swan et al.. QUATERNARY AMINE HYDROGEL WOUND 5,599.321 2/1997 Conway et al.. DRESSINGS 5,624,704 4/1997 Darouiche et al.. 5,670.557 9/1997 Dietz et al.. 75 Inventors: James J. Perrault, Vista, Calif.; 5,674.561 10/1997 Dietz et al.. Cameron G. Rouns, Pocatello, Id. 5,800,685 9/1998 Perrault. FOREIGN PATENT DOCUMENTS 73 Assignee: Ballard Medical Products, Draper, Utah 92/06694 4/1992 WIPO. WO 97/14448 4/1997 WIPO. 21 Appl. No.: 09/144,727 OTHER PUBLICATIONS 22 Filed: Sep. 1, 1998 I. I. Raad, “Vascular Catheters Impregnated with Antimi crobial Agents: Present Knowledge and Future Direction,” Related U.S. Application Data Infection Control and Hospital Epidemiology, 18(4): 63 Continuation-in-part of application No. 08/738,651, Oct. 28, 227–229 (1997). 1996, Pat. No. 5,800,685. R. O. Darouiche, H. Safar, and I. I. Raad, “In Vitro Efficacy of Antimicrobial-Coated Bladder Catheters in Inhibiting 51) Int. Cl." .......................... A61K31/785; A61F 13/00 Bacterial Migration along Catheter Surface,” J. Infect. Dis., 52 U.S. Cl. ..................................... 424/78.06; 424/78.08; 176: 1109-12 (1997). 424/78.35; 424/78.37; 424/443; 424/445 W. Kohen and B. Jansen, “Polymer Materials for the Pre 58 Field of Search ..................................... 424/443, 445, vention of Catheter-related Infections.” Zbl Bakt., 283: 424/78.06, 78.07, 78.08, 78.35, 78.37 175-186 (1995). -
Electrochemistry –An Oxidizing Agent Is a Species That Oxidizes Another Species; It Is Itself Reduced
Oxidation-Reduction Reactions Chapter 17 • Describing Oxidation-Reduction Reactions Electrochemistry –An oxidizing agent is a species that oxidizes another species; it is itself reduced. –A reducing agent is a species that reduces another species; it is itself oxidized. Loss of 2 e-1 oxidation reducing agent +2 +2 Fe( s) + Cu (aq) → Fe (aq) + Cu( s) oxidizing agent Gain of 2 e-1 reduction Skeleton Oxidation-Reduction Equations Electrochemistry ! Identify what species is being oxidized (this will be the “reducing agent”) ! Identify what species is being •The study of the interchange of reduced (this will be the “oxidizing agent”) chemical and electrical energy. ! What species result from the oxidation and reduction? ! Does the reaction occur in acidic or basic solution? 2+ - 3+ 2+ Fe (aq) + MnO4 (aq) 6 Fe (aq) + Mn (aq) Steps in Balancing Oxidation-Reduction Review of Terms Equations in Acidic solutions 1. Assign oxidation numbers to • oxidation-reduction (redox) each atom so that you know reaction: involves a transfer of what is oxidized and what is electrons from the reducing agent to reduced 2. Split the skeleton equation into the oxidizing agent. two half-reactions-one for the oxidation reaction (element • oxidation: loss of electrons increases in oxidation number) and one for the reduction (element decreases in oxidation • reduction: gain of electrons number) 2+ 3+ - 2+ Fe (aq) º Fe (aq) MnO4 (aq) º Mn (aq) 1 3. Complete and balance each half reaction Galvanic Cell a. Balance all atoms except O and H 2+ 3+ - 2+ (Voltaic Cell) Fe (aq) º Fe (aq) MnO4 (aq) º Mn (aq) b. -
Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters. -
Japan''s Effort in Management of Mercury Waste
S1_04 JapanJapan ’’’’’’ss EffortEffort inin ManagementManagement ofof MercuryMercury WasteWaste Outline of Mercury Waste Control in Japan Implementation of Battery /fluorescent light Separate ①①① Producer’s Efforts/ Initiative Collection ~~~Design for Environment ~~~ ■A lot of municipalities collects ■Achievement of Mercury-free dry mercury contained waste battery separately to join the nationwide ■Stop Mercurybattery production recovery system in cooperation (1995) with people. Proper Disposal ②②② Establishment of Mercury waste ③③③ Set proper standard for Collection & Recovery System ■ Nationwide Recovery system was mercury waste control established in 1986 by the Japan Waste ■Standard of soot in the exhaust gas Management Association, in closer from incinerator cooperation with a private recycler. ■Effluent standard for landfill site ■Criteria for industrial waste which can be carried into controlled landfill site, etc History of Mercury Reduction Efforts in Japan 1968 Minamata disease certificated as pollution- related illness 1973 Stop production of Mercurochrome Chlor-Alkali plant need closed-system by government (mercury method nearly 100%) 1983 Public anxiety on the risks of environmental pollution caused by waste battery which includes mercury through the waste treatment process 1986 Nation-wide collection & recycling system was established Mercury method of Chlor-Alkali plant became “ 0%” 1991 Mercury Free completed in Manganese Batteries 1992 Mercury Free completed in Alkaline Battery 1995 Stop production of Mercury Battery ① ProducerProducer’’’’ss Efforts/Initiative Central GovernmentGovernment’’’’ss Request to the Battery Association of Japan (BAJ)(BAJ)inin 1984 Ministry of Health and Ministry of International Trade & Industry requested BAJ (1) Reduction of mercury amount for battery (2) Expand of voluntary-collection of battery etc. Response by the BAJ in 1984 BAJ committed (1) Manufacturers of mercury battery never create new market. -
Vol. 83 Wednesday, No. 124 June 27, 2018 Pages 30031–30284
Vol. 83 Wednesday, No. 124 June 27, 2018 Pages 30031–30284 OFFICE OF THE FEDERAL REGISTER VerDate Sep 11 2014 19:16 Jun 26, 2018 Jkt 244001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\27JNWS.LOC 27JNWS daltland on DSKBBV9HB2PROD with FRONT MATTER WS II Federal Register / Vol. 83, No. 124 / Wednesday, June 27, 2018 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Subscriptions: Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Paper or fiche 202–512–1800 Committee of the Federal Register (1 CFR Ch. I). The Assistance with public subscriptions 202–512–1806 Superintendent of Documents, U.S. Government Publishing Office, Washington, DC 20402 is the exclusive distributor of the official General online information 202–512–1530; 1–888–293–6498 edition. Periodicals postage is paid at Washington, DC. Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making Paper or fiche 202–512–1800 available to the public regulations and legal notices issued by Assistance with public single copies 1–866–512–1800 Federal agencies. These include Presidential proclamations and (Toll-Free) Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Assistance with Federal agency subscriptions: Documents are on file for public inspection in the Office of the Email [email protected] Federal Register the day before they are published, unless the Phone 202–741–6000 issuing agency requests earlier filing. -
Risks to Health and the Environment Related to the Use of Mercury Products
Ref. Ares(2015)4242228 - 12/10/2015 Risks to Health and the Environment Related to the Use of Mercury Products Final Report prepared for The European Commission, DG Enterprise by Risk & Policy Analysts Limited, Farthing Green House, 1 Beccles Road, Loddon, Norfolk, NR14 6LT Tel: 01508 528465 Fax: 01508 520758 Email: [email protected] Web: www.rpaltd.co.uk RPA REPORT - ASSURED QUALITY Project: Ref/Title J372/Mercury Approach: In accordance with the Contract, Scoping Meeting with the Commission and associated discussions Report Status: Final Report Authors: Dr P Floyd & P Zarogiannis, RPA Dr M Crane, Crane Consultants Prof S Tarkowski, Nofer Institute of Occupational Medicine (Poland) Prof V Bencko, Charles University of Prague Approved for Issue by: Ms M Postle, Director Date: 9 August, 2002 If printed by RPA, this report will be on chlorine free, 100% recycled paper. Risk & Policy Analysts EXECUTIVE SUMMARY Overview Mercury and its compounds are hazardous materials which may pose risks to people and to the environment. This report presents an assessment of the risks associated with the use of mercury in a range of products. The key requirements of the study were: • to identify usage of mercury in dental amalgam, batteries, measuring instruments (such as thermometers and manometers), lighting, other electrical components and other lesser uses; • to review data used to evaluate the toxicity of mercury and mercury compounds to humans and to the environment; • to derive predicted environmental concentrations (PECs) associated with use of the products under consideration and compare with those associated with other sources of mercury; and • to characterise the associated risks.